Found: 8
Select item for more details and to access through your institution.
IRF2BP2 Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 8, p. 797, doi. 10.3390/ph14080797
- By:
- Publication type:
- Article
Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.738481
- By:
- Publication type:
- Article
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response.
- Published in:
- Clinical & Experimental Immunology, 2022, v. 210, n. 2, p. 141, doi. 10.1093/cei/uxac085
- By:
- Publication type:
- Article
Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice.
- Published in:
- Rheumatology, 2017, v. 56, n. 5, p. 725, doi. 10.1093/rheumatology/kew467
- By:
- Publication type:
- Article
The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.
- Published in:
- Rheumatology, 2015, v. 54, n. 6, p. 1103, doi. 10.1093/rheumatology/keu430
- By:
- Publication type:
- Article
Chronic back pain in patients with rheumatoid arthritis and in a control population: prevalence and disability—a 5-year follow-up.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Chronic back pain in patients with rheumatoid arthritis and in a control population: prevalence and disability—a 5-year follow-up.
- Published in:
- Rheumatology, 2011, v. 50, n. 9, p. 1635, doi. 10.1093/rheumatology/ker173
- By:
- Publication type:
- Article
Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 11, p. 2054, doi. 10.1002/art.42547
- By:
- Publication type:
- Article